Opinion

Video

Patient Case 2: Metastatic CSPC

Author(s):

Stephen J. Freedland, MDEleni Efstathiou, MD, PhD

Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.

Video content above is prompted by the following questions:

  • What is your initial impression of this patient and their risk stratification?
    • What biomarker testing and imaging would you recommend?
    • How would you assess the burden and distribution of metastatic disease?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
A panel of 3 experts on nasopharyngeal carcinoma
A panel of 3 experts on nasopharyngeal carcinoma
2 KOLs are featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
Ruben Olivares, MD
Related Content
US FDA
September 3rd 2024

FDA Green Lights Companion Diagnostics for Olaparib Plus Abiraterone Acetate in BRCA+ mCRPC

Karen L. Reckamp, MD, professor, medicine, medical oncology director, Lung Institute, director, Division of Medical Oncology, associate director, Clinical Research, Cedars-Sinai Medical Center
June 20th 2024

Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs

FDA
August 27th 2024

64Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PET Imaging in Prostate Cancer

D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles
April 15th 2024

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Kara N. Maxwell, MD, PhD, director, Men and BRCA Program, Basser Center, associate professor, medicine (hematology-oncology), Perelman School of Medicine, University of Pennsylvania
August 20th 2024

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 16th 2024

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC